From: Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure
Characteristic | Non-SHF group (n = 1976) | SHF group (n = 260) | P value |
---|---|---|---|
Age, yrs | 57.05 ± 9.77 | 71.06 ± 11.88 | 0.000 |
Male, % | 634 (32.3) | 154 (59.2) | 0.000 |
Weight, kg | 62.48 ± 10.39 | 65.22 ± 14.03 | 0.006 |
Height, cm | 160.81 ± 7.67 | 164.66 ± 8.98 | 0.000 |
Smoking, % | 413 (21.1) | 87 (33.5) | 0.000 |
Drinking, % | 268 (13.7) | 44 (16.9) | 0.156 |
Systolic BP, mmHg | 133.87 ± 22.07 | 131.57 ± 23.17 | 0.124 |
Diastolic BP, mmHg | 75.76 ± 11.77 | 76.27 ± 12.08 | 0.522 |
Heart rate, beats/min | 73.56 ± 11.16 | 79.17 ± 9.83 | 0.000 |
Echocardiography | Â | Â | Â |
 LAD, mm | 34.19 ± 4.86 | 46.72 ± 9.40 | 0.000 |
 LVESD, mm | 28.95 ± 4.18 | 43.60 ± 13.20 | 0.000 |
 LVEDD, mm | 46.66 ± 4.28 | 56.71 ± 12.41 | 0.000 |
 LVEF, % | 65.00 ± 3.08 | 39.15 ± 7.79 | 0.000 |
GRK5 | Â | Â | 0.817 |
 Gln41Gln, n (%) | 1380 (98.4) | 221 (98.2) |  |
 Gln41Leu, n (%) | 22 (1.6) | 4 (1.8) |  |
ADRB1 | Â | Â | 0.490 |
 Arg389Arg, n (%) | 756 (50.8) | 116 (50.9) |  |
 Arg389Gly, n (%) | 615 (41.3) | 99 (43.4) |  |
 Gly389Gly, n (%) | 117 (7.9) | 13 (5.7) |  |
Medication, n (%) | Â | Â | Â |
 ACE inhibitors | 47 (2.4) | 30 (11.5) | 0.000 |
 Angiotensin receptor blockers | 117 (6.0) | 66 (25.4) | 0.000 |
 Beta-blockers | 66 (3.4) | 87 (33.6) | 0.000 |
 Aldosterone antagonists | 3 (0.2) | 164 (63.1) | 0.000 |
 Diuretics | 17 (0.9) | 188 (72.3) | 0.000 |
 Digoxin | 3 (0.2) | 69 (26.5) | 0.000 |
 Statins | 36 (1.8) | 127 (48.8) | 0.000 |
 Nitrates | 13 (0.7) | 145 (55.8) | 0.000 |